2023 World Conference on Lung Cancer (Posters)-P2.09. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer

P2.09. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aimed to assess the real-world efficacy and safety of sotorasib, a drug approved by the FDA for patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). The study analyzed data from 128 patients who received sotorasib between June 2021 and February 2023, and compared the results to those from the clinical trial CodeBreaK100.<br /><br />The study found that the response rates, progression-free survival (PFS), and overall survival (OS) in the real-world cohort were comparable to those reported in the CodeBreaK100 trial. The objective response rate was 37.1%, median PFS was 6.8 months, and median OS was 12.5 months.<br /><br />Treatment-related adverse events led to sotorasib interruption or dose reduction in 22.2% of patients and discontinuation in 7.1% of patients. The most common toxicities leading to sotorasib discontinuation, interruption, or dose reduction were diarrhea, hepatotoxicity, and pneumonitis.<br /><br />The study also found that dose reduction for any reason was associated with improved PFS and OS, suggesting that lower doses of sotorasib may be just as effective but less toxic.<br /><br />Patients who received immune checkpoint inhibitors (ICIs) within 3 months of starting sotorasib had higher rates of sotorasib discontinuation, interruption, or dose reduction for toxicity.<br /><br />In terms of baseline characteristics, the real-world cohort of veterans treated with sotorasib was older, less fit, and more likely to be male compared to the CodeBreaK100 cohort.<br /><br />Overall, this real-world analysis provides evidence of the efficacy and safety of sotorasib in the U.S. veteran population with KRAS G12C-mutated advanced NSCLC. The study highlights the importance of considering real-world data in addition to clinical trial findings when evaluating the benefits and risks of a treatment.

Asset Subtitle

Katherine Zhou

Meta Tag

Speaker Katherine Zhou

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

sotorasib

KRAS G12C-mutated

NSCLC

response rates

progression-free survival

overall survival

clinical trial

adverse events

dose reduction

real-world analysis